Company Encyclopedia
View More
name
ANKE BIO
300009.SZ
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits.
1.579 T
300009.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking6/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.50%A
    • Profit Margin25.95%A
    • Gross Margin75.52%A
  • Growth ScoreD
    • Revenue YoY-6.81%D
    • Net Profit YoY-14.55%D
    • Total Assets YoY2.20%C
    • Net Assets YoY5.14%B
  • Cash ScoreD
    • Cash Flow Margin385.42%C
    • OCF YoY-6.81%D
  • Operating ScoreC
    • Turnover0.51C
  • Debt ScoreA
    • Gearing Ratio14.81%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next year

    On October 28th, ANKE BIO stated during an institutional research that the clinical trial progress of its independently developed "AK2017 Injection" is going smoothly, having completed the enrollment for Phase II clinical trials. It has now submitted a supplementary application for Phase III clinical trials and is expected to initiate Phase III clinical trials at the beginning of next year

    Zhitong·
    SZ
    300009
    +0.93%
    Zhitong·
    SZ
    300009
    +0.93%

    ANKE BIO released its performance for the first three quarters, with a net profit attributable to the parent company of 551 million yuan, a decrease of 6.48%

    According to the Zhitong Finance APP, ANKE BIO released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.963 billion yuan, a year-on-year increase of 2.15%. The net profit attributable to shareholders of the listed company was 551 million yuan, a year-on-year decrease of 6.48%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 519 million yuan, a year-on-year decrease of 6.56%. The basic earnings per share were 0.3297 yuan

    Zhitong·
    SZ
    300009
    +0.93%
    Zhitong·
    SZ
    300009
    +0.93%

    ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infections

    ANKE BIO held a Phase III clinical trial investigator meeting in Xiamen for two new drugs targeting respiratory viral infections in children, namely AK1012 inhalation solution and human interferon α2b spray. Both products are aimed at common diseases in children, with AK1012 being a modified new formulation designed to treat lower respiratory tract infections caused by respiratory syncytial virus, while the human interferon α2b spray is used for the treatment of herpetic pharyngitis in children

    Zhitong·
    SZ
    300009
    +0.93%
    Zhitong·
    SZ
    300009
    +0.93%

    ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting

    ANKE BIO announced that it will present the clinical research data of its innovative drug HuA21 at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The study of the drug in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric cancer has shown good anti-tumor activity and safety, supporting the Phase III clinical trial and enhancing the product's market competitiveness

    Zhitong·
    SZ
    300009
    +0.93%
    Zhitong·
    SZ
    300009
    +0.93%

    ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%

    ANKE BIO presented research results on HuA21 injection combined with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma at the 2025 European Society for Medical Oncology Annual Meeting. The study showed that the objective response rate in the HuA21 group was 80.8%, compared to 76.7% in the control group. A total of 60 patients were enrolled in the study, and the results indicated that HuA21 has good anti-tumor activity

    Zhitong·
    SZ
    300009
    +0.93%
    Zhitong·
    SZ
    300009
    +0.93%
    © 2025 Longbridge｜Disclaimer